Funding Wins For Lorviqua & Gazyvaro In England
Pfizer has dropped the price it was asking for Lorviqua, and evidence from the Cancer Drugs Fund appears to support the clinical trial evidence for Roche’s Gazyvaro.
You may also be interested in...
Roche’s Gazyvaro is the fifth drug to be recommended by UK HTA body NICE for use on an interim fund that gives manufacturers more time to gather evidence to prove their drugs are cost-effective and win long-term funding on the National Health Service.
Drug companies have their last chance to negotiate which documents and information Italy’s regulator, AIFA, will be entitled to request of them when they submit pricing and reimbursement applications.
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.